Moderna (MRNA) Ph2 Fully Enrolled, Morgan Stanley Reiterates Overweight
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $90.00 price target on Moderna (NASDAQ: MRNA) noting that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
